In a bid to find a viable treatment for the coronavirus, the Drugs Controller General of India has permitted the phase one human clinical trials for Antisera.
Antisera was developed by injecting inactivated SARS-CoV-2 in horses and can be a potential treatment for the coronavirus, as per ICMR officials. The drug has been developed by the ICMR itself along with a Hyderabad-based bio-pharmaceutical firm. The drug is blood serum high in antibodies against specific antigens and is injected in humans to help boost the immune system to battle specific infections. However, the Antisera is yet to undergo human clinical trials in order to establish safety and efficiency with regards to the treatment.
On the other hand, Mumbai’s civic body, Brihanmumbai Municipal Corporation (BMC) had earlier stated that the Indian Council of Medical Research (ICMR) is conducting a study to gauge the feasibility of the Bacillus Calmette–Guérin vaccine, more commonly known as BCG, to combat COVID-19 among the elderly.
As per reports, the BMC, speaking to the media has stated that the BCG is a vaccine regularly used for tuberculosis as well as leprosy. This vaccine will be jointly studied by experts at the Seth GS Medical College, KEM Hospital, as well as the Public Health Department.
Share
Tweet
